Impact BioMedical Inc. (IBO) is a pre-revenue-stage pharmaceutical IP licensing and development company with a balance sheet dominated by finite-lived intangible assets and a chronic cash deficit. Under the liquidation lens, equity recovery is deeply negative and deteriorating quarter-over-quarter. The MFFAIS-computed cash liquidation value is -$1.16M, liquid liquidation value is -$1.15M, and operating liquidation value is -$1.09M as of March 31, 2026, confirming zero equity recovery under any reasonable liquidation scenario. The asset side is structurally impaired for liquidation purposes: cash stands at $20K (100% recovery but immaterial), notes receivable current at $199K (maturity being renegotiated, counterparty secured by Florida real property, some recovery expected but at discount), inventory of $63K (filtration systems, ~60% recovery), and finite-lived intangibles of $16.7M net carrying value (developed technology $16.4M net, acquired Celios IP $292K net) — all of which receive a 0% recovery haircut under the liquidation lens. The liability stack, while reduced materially from the prior year by the October 2025 conversion of a ~$15M revolving related-party note into 31.9M shares of common stock, now consists primarily of a demand-callable, unsecured related-party payable to DSS Inc. that grew from $621K at December 31, 2025 to $1.10M at March 31, 2026 — a $482K increase in one quarter driven entirely by related-party borrowings to fund operations. Accounts payable and accrued expenses are modest. GAAP total equity including noncontrolling interest is reported at $14.7M, but this is almost entirely attributable to the carrying value of intangible assets that liquidate at zero. Operating cash burn was $464K in Q1 2026 (improved from $682K in Q1 2025), but the improvement is partially masked by $1.44M in non-cash stock-based compensation issued in January 2026 to executives, directors, and consultants — a material dilution event with no balance-sheet asset offset. Going concern language is explicit and unqualified. The filing does not tag any balance sheet line items in XBRL (TAG_CONTEXT is empty), so all numerical references are drawn from the narrative and financial statement prose. The absence of XBRL tagging for balance sheet items prevents tag-level analysis but does not change the qualitative assessment: the company is insolvent on a liquidation basis, has $20K in cash against recurring quarterly cash burn of ~$464K, and is dependent on demand-callable related-party advances from a controlling 86% shareholder to remain operational. The prior filing (10-K for fiscal year ended December 31, 2025) confirms the note payable extinguishment via equity conversion was the dominant balance sheet event of 2025, removing ~$9.1M in face-value debt. However, the structural shortfall persists because intangible assets — the company's primary balance sheet item — carry zero liquidation value.
▼ Community Notes